Finding the needle in the haystack: why high-throughput screening is good for your health

被引：28

作者：

Aherne, GW ^{[1
]}

McDonald, E ^{[1
]}

Workman, P ^{[1
]}

机构：

[1] Inst Canc Res, Canc Res UK, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England

来源：

BREAST CANCER RESEARCH | 2002年 / 4卷 / 04期

关键词：

chemistry; drug discovery; high-throughput screening; new molecular targets;

D O I：

10.1186/bcr440

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High-throughput screening is an essential component of the toolbox of modern technologies that improve speed and efficiency in contemporary cancer drug development. This is particularly important as we seek to exploit, for maximum therapeutic benefit, the large number of new molecular targets emerging from the Human Genome Project and cancer genomics. Screening of diverse collections of low molecular weight compounds plays a key role in providing chemical starting points for iterative optimisation by medicinal chemistry. Examples of successful drug discovery programmes based on high-throughput screening are described, and these offer potential in the treatment of breast cancer and other malignancies.

引用

页码：148 / 154

页数：7

共 53 条

[1] AHERNE GW, 2002, ANTI-CANCER DRUG DES, P249
[2] Chemical genetic approaches for the elucidation of signaling pathways
Alaimo, PJ
Shogren-Knaak, MA
Shokat, KM
[J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2001, 5 (04) : 360 - 367
[3] ALESSI DR, 1995, METHOD ENZYMOL, V255, P279
[4] ZD1839 ('Iressa')1,2 as an anticancer agent
Baselga, J
Averbuch, SD
[J]. DRUGS, 2000, 60 (Suppl 1) : 33 - 40
[5] Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2
Basso, AD
Solit, DB
Munster, PN
Rosen, N
[J]. ONCOGENE, 2002, 21 (08) : 1159 - 1166
[6] Re:: Levels of hypoxia-inducible factor-1α during breast carcinogenesis -: Response
Bos, R
van Diest, PJ
van der Wall, E
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (15) : 1177 - 1177
[7] Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
Chen, YNP
Sharma, SK
Ramsey, TM
Jiang, L
Martin, MS
Baker, K
Adams, PD
Bair, KW
Kaelin, WG
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) : 4325 - 4329
[8] ST1571 (Gleevec™) as a paradigm for cancer therapy
Druker, BJ
[J]. TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) : S14 - S18
[9] Cell-based assays for identification of novel double-strand break-inducing agents
Dunstan, HM
Ludlow, C
Goehle, S
Cronk, M
Szankasi, P
Evans, DRH
Simon, JR
Lamb, JR
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (02): : 88 - 94
[10] Discovery of small-molecule inhibitors of bcl-2 through structure-based computer screening
Enyedy, IJ
Ling, Y
Nacro, K
Tomita, Y
Wu, XH
Cao, YY
Guo, RB
Li, BH
Zhu, XF
Huang, Y
Long, YQ
Roller, PP
Yang, DJ
Wang, SM
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (25) : 4313 - 4324

← 1 2 3 4 5 6 →